Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology | Neurology
Disease Category: Schizophrenia and Schizoaffective Disorders
Location: United States, IL

Clinical Trial Details

Overview

Research Study Summary

A phase 2, multicenter, double-blind placebo-controlled comparator study of 2 doses of LY2140023 versus placebo in patients with DSM-IV-TR Schizophrenia.

Purpose

The primary purpose of your participation in this study is to help answer the following research question(s), and not to provide you treatment for your condition:

  • Whether LY2140023 can help subjects/patients with schizophrenia.
  • Whether LY2140023 can help subjects/patients with schizophrenia who have certain DNA.
You must be willing and able to stay in the hospital for a minimum of 21 days.

Please contact Alexian Brothers for more information on participation.

To Learn more
Phase

2

Gender

Both Male and Female

Age

N/A

Overall Status

Recruiting

Duration

21 Days

Facility Type

N/A

Contact

Alexian Brothers Hospital Network
1786 Moon Lake Boulevard, Suite 200
Hoffman Estates, IL 60169
Phone: 847-230-3599

View Map

Research Center Information: Alexian Brothers Hospital Network

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

Name:
Address:
City:
State:
Zip/Postal Code:
Country:
Phone:
Email:  
Message:
 
Please leave this field empty.

CW ID: 176870

Date Last Changed: July 22, 2013


DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.